Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1187886

Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10

Bates, Emily A.; Davies, James A.; Vanova, Jana; Nestić, Davor; Meniel, Valerie S; Koushyar, Sarah; Cunliffe, Tabitha G.; Mundy, Rosie M.; Moses, Elise; Uusi-Kerttula, Hanni K. et al.
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10 // Molecular Therapy - Oncolytics, 25 (2022), 43-56 doi:10.1016/j.omto.2022.03.007 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 1187886 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10

Autori
Bates, Emily A. ; Davies, James A. ; Vanova, Jana ; Nestić, Davor ; Meniel, Valerie S ; Koushyar, Sarah ; Cunliffe, Tabitha G. ; Mundy, Rosie M. ; Moses, Elise ; Uusi-Kerttula, Hanni K. ; Baker, Alexander T. ; Cole, David K. ; Majhen, Dragomira ; Rizkallah, Pierre J. ; Phesse, Toby ; Chester, John D ; Parker, Alan L.

Izvornik
Molecular Therapy - Oncolytics (2372-7705) 25 (2022); 43-56

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
oncolytic ; virotherapy ; adenovirus targeting ; αvβ6 integrin ; low seroprevalence ; structure

Sažetak
Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) derived from HAdV with naturally low rates of pre- existing immunity will be beneficial for future clinical translation. We generated a low- seroprevalence HAdV-D10 serotype vector incorporating an αvβ6 integrin-selective peptide, A20, to target αvβ6-positive tumor cell types. HAdV-D10 has limited natural tropism. Structural and biological studies of HAdV-D10 knob protein highlighted low-affinity engagement with native adenoviral receptors CAR and sialic acid. HAdV-D10 fails to engage blood coagulation factor X, potentially eliminating “off-target” hepatic sequestration in vivo. We engineered an A20 peptide that selectively binds αvβ6 integrin into the DG loop of HAdV-D10 fiber knob. Assays in αvβ6+ cancer cell lines demonstrated significantly increased transduction mediated by αvβ6-targeted variants compared with controls, confirmed microscopically. HAdV-D10.A20 resisted neutralization by neutralizing HAdV-C5 sera. Systemic delivery of HAdV-D10.A20 resulted in significantly increased GFP expression in BT20 tumors. Replication-competent HAdV-D10.A20 demonstrated αvβ6 integrin-selective cell killing in vitro and in vivo. HAdV-D10 possesses characteristics of a promising virotherapy, combining low seroprevalence, weak receptor interactions, and reduced off-target uptake. Incorporation of an αvβ6 integrin-selective peptide resulted in HAdV-D10.A20, with significant potential for clinical translation.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Interdisciplinarne prirodne znanosti



POVEZANOST RADA

Projekti:
HRZZ-IP-2019-04-6048 - Endocitoza adenovirusa i urođeni imunosni odgovor (AdenoIN) (Majhen, Dragomira, HRZZ - 2019-04) ( CroRIS)

Ustanove:
Institut "Ruđer Bošković", Zagreb

Profili:

Avatar Url Dragomira Majhen (autor)

Avatar Url Davor Nestić (autor)

Poveznice na cjeloviti tekst rada:

doi www.sciencedirect.com doi.org fulir.irb.hr

Citiraj ovu publikaciju:

Bates, Emily A.; Davies, James A.; Vanova, Jana; Nestić, Davor; Meniel, Valerie S; Koushyar, Sarah; Cunliffe, Tabitha G.; Mundy, Rosie M.; Moses, Elise; Uusi-Kerttula, Hanni K. et al.
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10 // Molecular Therapy - Oncolytics, 25 (2022), 43-56 doi:10.1016/j.omto.2022.03.007 (međunarodna recenzija, članak, znanstveni)
Bates, E., Davies, J., Vanova, J., Nestić, D., Meniel, V., Koushyar, S., Cunliffe, T., Mundy, R., Moses, E. & Uusi-Kerttula, H. (2022) Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics, 25, 43-56 doi:10.1016/j.omto.2022.03.007.
@article{article, author = {Bates, Emily A. and Davies, James A. and Vanova, Jana and Nesti\'{c}, Davor and Meniel, Valerie S and Koushyar, Sarah and Cunliffe, Tabitha G. and Mundy, Rosie M. and Moses, Elise and Uusi-Kerttula, Hanni K. and Baker, Alexander T. and Cole, David K. and Majhen, Dragomira and Rizkallah, Pierre J. and Phesse, Toby and Chester, John D and Parker, Alan L.}, year = {2022}, pages = {43-56}, DOI = {10.1016/j.omto.2022.03.007}, keywords = {oncolytic, virotherapy, adenovirus targeting, αvβ6 integrin, low seroprevalence, structure}, journal = {Molecular Therapy - Oncolytics}, doi = {10.1016/j.omto.2022.03.007}, volume = {25}, issn = {2372-7705}, title = {Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10}, keyword = {oncolytic, virotherapy, adenovirus targeting, αvβ6 integrin, low seroprevalence, structure} }
@article{article, author = {Bates, Emily A. and Davies, James A. and Vanova, Jana and Nesti\'{c}, Davor and Meniel, Valerie S and Koushyar, Sarah and Cunliffe, Tabitha G. and Mundy, Rosie M. and Moses, Elise and Uusi-Kerttula, Hanni K. and Baker, Alexander T. and Cole, David K. and Majhen, Dragomira and Rizkallah, Pierre J. and Phesse, Toby and Chester, John D and Parker, Alan L.}, year = {2022}, pages = {43-56}, DOI = {10.1016/j.omto.2022.03.007}, keywords = {oncolytic, virotherapy, adenovirus targeting, αvβ6 integrin, low seroprevalence, structure}, journal = {Molecular Therapy - Oncolytics}, doi = {10.1016/j.omto.2022.03.007}, volume = {25}, issn = {2372-7705}, title = {Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10}, keyword = {oncolytic, virotherapy, adenovirus targeting, αvβ6 integrin, low seroprevalence, structure} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus

Citati:

    Altmetrijski pokazatelji:


    Podijeli:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font
    CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.